Combined
radiotherapy (RT) and chemotherapy are prescribed to patients
with advanced prostate cancer (PCa) to increase their survival; however,
radiation-related side effects and systematic toxicity caused by chemotherapeutic
drugs are unavoidable. To improve the precision and efficacy of concurrent
RT and chemotherapy, we have developed a PCa-targeted gold nanocluster
radiosensitizer conjugated with a highly potent cytotoxin, monomethyl
auristatin E, PSMA-AuNC-MMAE, for RT and chemotherapy of PCa. This
approach resulted in enhanced uptake of NCs by PSMA-positive cancer
cells, targeted chemotherapy, and increased efficacy of RT both in vitro and in vivo. In addition, the
combination of gold and MMAE further increased the efficacy of either
of the agents delivered alone or simultaneously but not covalently
linked. The PSMA-AuNC-MMAE conjugates improve the specificity and
efficacy of radiation and chemotherapy, potentially reducing the toxicity
of each therapy and making this an attractive avenue for clinical
treatment of advanced PCa.